PreciseDx Announces Publication in Breast Cancer Research; Validates Its AI-Enabled Platform that Predicts Early-Stage Breast Cancer Recurrence Better than Current Industry Standard

Study analyzes more than 2,000 patient samples, confirming the technology delivers more accurate, objective, diagnostic data than traditional testing NEW YORK, Jan. 19, 2023 /PRNewswire/ -- PreciseDx, a leading innovator in AI-powered, patient-specific disease analysis, today announced...

Click to view original post